|Research Assistant Professor
Ph.D., Pathology & Physiology, College of Medicine, Zhejiang University, China
Postdoctoral fellowship, Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences
van Rhee F, Szmania S, Dillon M, van Abbema A, Li X, Stone M, Garg TK, Shi J, Bost-Moreno AM, Yun R, Balasa B, Ganguly B, Chao D, Rice AG, Zhan F, Shaughnessy J, Barlogie B, Yaccoby S, Afar DEH. Combinatorial efficacy of anti-CS1 monoclonal antibody elotuzumab (HuLuc63) and bortezomib against multiple myeloma. Molecular Cancer Therapeutics. 2009 Sep 8(9): 2616-24.
Li X, Ling W, Pennisi A, Khan S, Yaccoby S. Fenretinide inhibits myeloma cell growth, osteoclastogenesis and osteoclast viability. Cancer Lett. 2009 May 14; 284 (2): 175-181.
Li X, Pennisi A, Yaccoby S. Role of decorin in the antimyeloma effects of osteoblasts. Blood. 2008 Jul 1; 112(1):159-68.
Yaccoby S, Pennisi A, Li X, Dillon SR, Zhan F, Barlogie B, Shaughnessy JD Jr. Atacicept (TACI-Ig) inhibits growth of TACI high primary myeloma cells in SCID-hu mice and in co-culture with osteoclasts. Leukemia. 2008 Feb; 22(2):406-13.
Li X, Pennisi A, Zhan F, Sawyer JR, Shaughnessy JD, Yaccoby S. Establishment and exploitation of hyperdiploid and nonhyperdiploid human myeloma cell lines. British Journal of Haematology. 2007,138: 802-811